<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642875</url>
  </required_header>
  <id_info>
    <org_study_id>PerOsEnteral1</org_study_id>
    <nct_id>NCT01642875</nct_id>
  </id_info>
  <brief_title>Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy</brief_title>
  <official_title>Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatoduodenectomy carries high morbidity rates even in high-volume centers. Postoperative&#xD;
      complications often preclude or delay adequate oral nutrition and nutritional support may be&#xD;
      required. However, the role of perioperative nutritional supplementation in well-nourished&#xD;
      patients remains controversial.&#xD;
&#xD;
      The purpose of this study is to compare the influence of early enteral and oral nutrition on&#xD;
      postoperative course and complications after pancreatoduodenectomy.&#xD;
&#xD;
      96 patients undergoing pancreatoduodenectomy will be randomized to receive early enteral&#xD;
      nutrition (EN group) or early oral nutrition (PerOs group). The EN group will receive&#xD;
      standard enteral diet administered through a nasojejunal tube. Enteral nutrition will be&#xD;
      started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated&#xD;
      level. The PerOs group will receive oral diets beginning from the 2nd postoperative day and&#xD;
      oral intake will be advanced as tolerated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background &amp; aim: Pancreatoduodenectomy carries high morbidity rates even in high-volume&#xD;
      centers. Postoperative complications often preclude or delay adequate oral nutrition and&#xD;
      nutritional support may be required. However, the role of perioperative nutritional&#xD;
      supplementation in well-nourished patients remains controversial. There are not any standard&#xD;
      protocols for nutritional support after major upper gastrointestinal surgery in these&#xD;
      patients and postoperative nutritional regimens depend mainly upon surgeon's or center&#xD;
      preference.&#xD;
&#xD;
      Patients undergoing pancreatoduodenectomy often begin oral intake a week after operation and&#xD;
      enteral or parenteral nutrition is used to cover the daily caloric requirements during this&#xD;
      period, although their role still remains questionable. The safety of early oral nutrition&#xD;
      has been confirmed in the majority of gastrointestinal procedures. However, pancreatic&#xD;
      surgeons are quite reluctant to advance oral diet within the first postoperative week after&#xD;
      pancreatoduodenectomy due to fear of anastomosis breakdown or delayed gastric emptying&#xD;
      syndrome. These two postoperative nutritional regimens, early oral vs. early enteral&#xD;
      nutrition, have not been sufficiently evaluated in a prospective, randomized study.&#xD;
&#xD;
      Material and Methods: 96 patients undergoing pancreatoduodenectomy will be randomized to&#xD;
      receive early enteral nutrition (EN group) or early oral nutrition (PerOs group). The EN&#xD;
      group will receive standard enteral diet administered through a nasojejunal tube. The enteral&#xD;
      nutrition will be started on the 1st postoperative day and increased daily by 20-40 ml up to&#xD;
      the estimated level. The PerOs group will receive oral diets beginning from the 2nd&#xD;
      postoperative day and oral intake will be advanced as tolerated.&#xD;
&#xD;
      Purpose: The purpose of this study is to compare the influence of early enteral and oral&#xD;
      nutrition on postoperative course and complications after pancreatoduodenectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of delayed gastric emptying</measure>
    <time_frame>30 days after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity rate</measure>
    <time_frame>60 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality rate</measure>
    <time_frame>60 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay length</measure>
    <time_frame>60 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to full oral nutrition</measure>
    <time_frame>60 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of paralytic ileus</measure>
    <time_frame>7 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization rate</measure>
    <time_frame>30 days after discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Cancer of the Duodenum</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>EN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early enteral nutrition with standard enteral formulas administered through a nasojejunal tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PerOs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>early oral nutrition with hospital diets and oral formulas</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enteral nutrition</intervention_name>
    <description>Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.</description>
    <arm_group_label>EN</arm_group_label>
    <other_name>standard enteral formula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral nutrition</intervention_name>
    <description>Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated</description>
    <arm_group_label>PerOs</arm_group_label>
    <other_name>oral diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary periampullary tumor&#xD;
&#xD;
          -  R0, R1 resection&#xD;
&#xD;
          -  Chronic pancreatitis requiring pancreatoduodenectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic tumor&#xD;
&#xD;
          -  Locally unresectable tumor&#xD;
&#xD;
          -  Previous gastric resection&#xD;
&#xD;
          -  ASA IV-V&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Preoperative complete parenteral or enteral feeding&#xD;
&#xD;
          -  Immunosuppressive therapy before operation&#xD;
&#xD;
          -  Severe malnutrition&#xD;
&#xD;
          -  Lack of the patient's consent for the trial participation, feeding tube insertion or&#xD;
             epidural analgesia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Słodkowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marek Wronski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maciej Słodkowski, MD</last_name>
    <phone>0048 22 599 2251</phone>
    <email>maciejslodkowski@wp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marek Wroński, MD</last_name>
    <phone>0048 22 599 2482</phone>
    <email>mwronski@vp.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sp Csk Wum</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Wroński, MD,PhD</last_name>
      <phone>+48225992482</phone>
      <email>mwronski@vp.pl</email>
    </contact>
    <contact_backup>
      <last_name>Marcin Makiewicz, MD</last_name>
      <phone>+48225992252</phone>
      <email>marcin.makiewicz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Periampullary tumor</keyword>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Pancreatoduodenectomy</keyword>
  <keyword>Oral Nutrition</keyword>
  <keyword>Enteral Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Duodenal Neoplasms</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

